IN THE CLAIMS

Please amend the claims as follows. This listing of claims replaces all previous listings.

Claims 1-2. (canceled)

- 3. (currently amended) A method for identifying a candidate compound as a suitable pro-drug, comprising:
- (a) providing the candidate compound having an esterified phosphonate group or an esterified carboxyl group;
- (b) contacting the candidate compound with an <u>at least a partially purified fraction of a peripheral blood mononuclear cell (PBMC) extract comprising GS-7340 Ester Hydrolase activity extract of peripheral blood mononuclear cells (PBMCs) having carboxylic ester hydrolase activity to produce a metabolite compound;</u>
- (c) identifying the candidate compound as a suitable pro-drug if the metabolite compound has a phosphonic acid group instead of the esterified phosphonate group of the candidate compound, or a carboxylic acid group instead of the esterified carboxyl group of the candidate compound.

Claims 4-29. (canceled)

- 30. (previously presented) The method of claim 3, wherein said contacting step comprises contacting the candidate compound with at least a partially purified fraction of a PBMC extract comprising GS-7340 Ester Hydrolase *in vitro*.
- 31. (previously presented) The method of claim 3, wherein said contacting step comprises contacting the candidate compound with at least a partially purified fraction of a PBMC extract comprising GS-7340 Ester Hydrolase in cell culture.
 - 32. (previously presented) The method of claim 31, wherein said contacting step

comprises contacting the candidate compound with at least a partially purified fraction of a PBMC extract comprising GS-7340 Ester Hydrolase in a culture of peripheral blood mononuclear cells.

- 33. (previously presented) A method for identifying a candidate compound as a suitable pro-drug, comprising:
 - (a) providing the candidate compound having an esterified phosphonate group;
- (b) contacting the candidate compound with at least a partially purified fraction of a PBMC extract comprising GS-7340 Ester Hydrolase to produce a metabolite compound;
- (c) identifying the candidate compound as a suitable pro-drug if the metabolite compound has a phosphonic acid group instead of the esterified phosphonate group of the candidate compound.

Claims 34-61. (canceled)

- 62. (previously presented) The method of claim 33, wherein said contacting step comprises contacting the candidate compound with said extract comprising GS-7340 Ester Hydrolase *in vitro*.
- 63. (previously presented) The method of claim 33, wherein said contacting step comprises contacting the candidate compound with said extract comprising GS-7340 Ester Hydrolase in cell culture.
- 64. (previously presented) The method of claim 63, wherein said contacting step comprises contacting the candidate compound with said extract comprising GS-7340 Ester Hydrolase in a culture of peripheral blood mononuclear cells.
- 65. (previously presented) A method for identifying a candidate compound as a suitable pro-drug, comprising:
 - (a) providing the candidate compound having an esterified carboxyl group;

- (b) contacting the candidate compound with at least a partially purified fraction of a PBMC extract comprising GS-7340 Ester Hydrolase to produce a metabolite compound;
- (c) identifying the candidate compound as a suitable pro-drug if the metabolite compound has a carboxylic acid group instead of the esterified carboxyl group of the candidate compound.

Clams 66-92. (canceled)

- 93. (previously presented) The method of claim 65, wherein said contacting step comprises contacting the candidate compound with said extract comprising GS-7340 Ester Hydrolase *in vitro*.
- 94. (previously presented) The method of claim 65, wherein said contacting step comprises contacting the candidate compound with said extract comprising GS-7340 Ester Hydrolase in cell culture.
- 95. (previously presented) The method of claim 94, wherein said contacting step comprises contacting the candidate compound with said extract comprising GS-7340 Ester Hydrolase in a culture of peripheral blood mononuclear cells.
- 96. (currently amended) A method for identifying a candidate compound as a suitable pro-drug, comprising:
- (a) providing the candidate compound having an esterified phosphonate group or an esterified carboxyl group;
- (b) contacting the candidate compound with an <u>at least a partially purified fraction of PMBC extract comprising GS-7340 Ester Hydrolase activity, extract of peripheral blood mononuclear cells (PBMCs)</u> which has carboxylic ester hydrolase activity but does not cleave alpha-napthyl acetate, to produce a metabolite compound;
- (c) identifying the candidate compound as a suitable pro-drug if the metabolite compound has a phosphonic acid group instead of the esterified phosphonate group of the

Murty N. Arimilli *et al.* Appl. No. 10/740,694

candidate compound, or a carboxylic acid group instead of the esterified carboxyl group of the candidate compound.

Claims 97-122. (canceled)

123. (previously presented) The method of claim 96, wherein said contacting step comprises contacting the candidate compound with at least a partially purified fraction of a PBMC extract comprising GS-7340 Ester Hydrolase *in vitro*.

124. (previously presented) The method of claim 96, wherein said contacting step comprises contacting the candidate compound with at least a partially purified fraction of a PBMC extract comprising GS-7340 Ester Hydrolase in cell culture.

125. (previously presented) The method of claim 124, wherein said contacting step comprises contacting the candidate compound with at least a partially purified fraction of a PBMC extract comprising GS-7340 Ester Hydrolase in a culture of peripheral blood mononuclear cells.

Claims 126-180. (canceled)